Checkpoint inhibitor–induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective

Abstract Immune checkpoint inhibitors have transformed the treatment of hematolymphoid malignancies by enhancing antitumor immunity. These agents are associated with immune-related adverse events (irAEs), including hematologic toxicities such as autoimmune hemolytic anemia, immune-related thrombocyt...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Chokri Ben Lamine, Amr Hanbali, Ghada ElGohary, Hanan Alkhaldi, Riad El Fakih, Mahmoud Aljurf
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Springer Nature 2026-05-01
Sarja:	Blood Research
Aiheet:	Check point inhibitor Hematological Outcome Toxicities Auto-immune Cytopenia
Linkit:	https://doi.org/10.1007/s44313-026-00135-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!